Defining adult asthma endotypes by clinical features and patterns of volatile organic compounds in exhaled air

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Meyer, Norbert ^a,b   Dallinga, Jan W ^c   Nuss, Sarah Janine ^a   Moonen, Edwin JC ^c   van Berkel, Joep JBN ^c   Akdis, Cezmi ^d   van Schooten, Frederik Jan ^c   Menz, Günter ^a  

^a High Altitude Clinic (Hochgebirgsklinik) Davos   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Asthma; Cluster; Endotypes; Exhaled air; Phenotype; Volatile organic compounds

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; STEROID; THEOPHYLLINE; VOLATILE ORGANIC COMPOUND; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASTHMA; BREATH ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; EXPIRED AIR; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; OXIDATIVE STRESS; SENSITIVITY AND SPECIFICITY; SENSITIZATION; CASE CONTROL STUDY; CLASSIFICATION; CLUSTER ANALYSIS; DISCRIMINANT ANALYSIS; EXHALATION; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE;

ADULT; ASTHMA; BIOMARKERS; BREATH TESTS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; DISCRIMINANT ANALYSIS; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LUNG; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; VOLATILE ORGANIC COMPOUNDS;

EID: 84978110553     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-014-0136-8     Document Type: Article

References (27)

1. Wenzel SE: Asthma: defining of the persistent adult phenotypes. Lancet. 2006, 368: 804-813. 10.1016/S0140-6736(06)69290-8.
2. Moore WC, Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2009, 181: 315-323. 10.1164/rccm.200906-0896OC.
3. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, Wenzel SE, Aujla S, Castro M, Bacharier LB, Gaston BM, Bleecker ER, Moore WC: Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011, 127: 382-389. 10.1016/j.jaci.2010.11.015. e1
4. Anderson GP: Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008, 372: 1107-1119. 10.1016/S0140-6736(08)61452-X.
5. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF, Wardlaw AJ, Wenzel SE, Greenberger PA: Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011, 127 (2): 355-360. 10.1016/j.jaci.2010.11.037.
6. Van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen E, Wouters EF, Van Schooten FJ: Development of accurate classification method based on the analysis of volatile organic compounds from human exhaled air. J Chromatogr B Analyt Technol Biomed Life Sci. 2008, 861: 101-107. 10.1016/j.jchromb.2007.11.008.
7. Dallinga JW, Robroeks CM, van Berkel JJ, Moonen EJ, Godschalk RW, Jobsis Q, Dompeling E, Wouters EF, van Schooten FJ: Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy. 2009, 40: 68-76.
8. Pauling L, Robinson AB, Teranishi R, Cary P: Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A. 1971, 68: 2374-2376. 10.1073/pnas.68.10.2374.
9. Miekisch W, Schubert JK, Noeldge-Schomburg GF: Diagnostic potential of breath analysis--focus on volatile organic compounds. Clin Chim Acta. 2004, 347: 25-39. 10.1016/j.cccn.2004.04.023.
10. Phillips M, Gleeson K, Hughes JM, Greenberg J, Cataneo RN, Baker L, McVay WP: Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet. 1999, 353: 1930-1933. 10.1016/S0140-6736(98)07552-7.
11. Robroeks CM, van Berkel JJ, Dallinga JW, Jobsis Q, Zimmermann LJ, Hendriks HJ, Wouters MF, van der Grinten CP, van de Kant KD, van Schooten FJ, Dompeling E: Metabolomics of volatile organic compounds in cystic fibrosis patients and controls. Pediatr Res. 2010, 68: 75-80. 10.1203/PDR.0b013e3181df4ea0.
12. Van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen EJ, Wouters EF, Van Schooten FJ: A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med. 2009, 104: 557-563. 10.1016/j.rmed.2009.10.018.
13. Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, Cheung D, Bel EH, Sterk PJ: Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2009, 180: 1076-1082. 10.1164/rccm.200906-0939OC.
14. Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ: Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax. 2011, 66: 804-809. 10.1136/thx.2010.156695.
15. van der Schee MP, Palmay R, Cowan JO, Taylor DR: Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy. 2013, 43: 1217-1225. 10.1111/cea.12147.
16. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR: Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999, 14: 902-907. 10.1034/j.1399-3003.1999.14d29.x.
17. Akdis CA: Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012, 18: 736-749. 10.1038/nm.2754.
18. Dillard CJ, Tappel AL: Lipid peroxidation products in biological tissues. Free Radic Biol Med. 1989, 7: 193-196. 10.1016/0891-5849(89)90014-2.
19. Orhan H: Analyses of representative biomarkers of exposure and effect by chromatographic, mass spectrometric, and nuclear magnetic resonance techniques: method development and application in life sciences. J Sep Sci. 2007, 30: 149-174. 10.1002/jssc.200600322.
20. Paredi P, Kharitonov SA, Barnes PJ: Elevation of exhaled ethane concentration in asthma. Am J Respir Crit Care Med. 2000, 162: 1450-1454. 10.1164/ajrccm.162.4.2003064.
21. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ: Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000, 162: 369-373. 10.1164/ajrccm.162.2.9909025.
22. Kokoszka J, Nelson RL, Swedler WI, Skosey J, Abcarian H: Determination of inflammatory bowel disease activity by breath pentane analysis. Dis Colon Rectum. 1993, 36: 597-601. 10.1007/BF02049868.
23. Humad S, Zarling E, Clapper M, Skosey JL: Breath pentane excretion as a marker of disease activity in rheumatoid arthritis. Free Radic Res Commun. 1988, 5: 101-106. 10.3109/10715768809066917.
24. Boots AW, van Berkel JJ, Dallinga JW, Smolinska A, Wouters EF, van Schooten FJ: The versatile use of exhaled volatile organic compounds in human health and disease. J Breath Res. 2012, 6: 027108-10.1088/1752-7155/6/2/027108.
25. Lloyd CM, Hessel EM: Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol. 2010, 10 (12): 838-848. 10.1038/nri2870.
26. Dougherty RH, Sidhu SS, Raman K, Solon M, Solberg OD, Caughey GH, Woodruff PG, Fahy JV: Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol. 2010, 125: 1046-1053. 10.1016/j.jaci.2010.03.003. e8
27. Bisgaard H, Pipper CB, Bonnelykke K: Endotyping early childhood asthma by quantitative symptom assessment. J Allergy Clin Immunol. 2011, 127: 1155-1164. 10.1016/j.jaci.2011.02.007. e2